LianBio (LIANY)
- Previous Close
0.2980 - Open
0.2980 - Bid --
- Ask --
- Day's Range
0.2808 - 0.3097 - 52 Week Range
0.2410 - 4.9900 - Volume
10,871 - Avg. Volume
872,363 - Market Cap (intraday)
30.344M - Beta (5Y Monthly) -0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date Apr 29, 2024 - May 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Mar 15, 2024
- 1y Target Est
4.80
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
www.lianbio.comRecent News: LIANY
Performance Overview: LIANY
Trailing total returns as of 4/27/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LIANY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LIANY
Valuation Measures
Market Cap
30.34M
Enterprise Value
-219.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.15
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
2.08
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.67%
Return on Equity (ttm)
-32.42%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-87.98M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
252.22M
Total Debt/Equity (mrq)
1.20%
Levered Free Cash Flow (ttm)
-36.86M